CYP3A5*1 is an Inhibitory Factor for Lung Cancer in Taiwanese

CYP3A5*1是台灣肺癌患者的抑制因子

葉坤土(Kun-Tu Yeh) ； 陳瑞彰(Jui-Chang Chen) ； 陳志玫(Chih-Mei Chen) ； 王毓芬(Yu-Fen Wang) ； 李黛苹(Tai-Ping Lee) ； 張建國(Jan-Gowth Chang)

《The Kaohsiung Journal of Medical Sciences》 19卷5期 (2003/05) Pp. 201-207

摘要

CYP3A5酵素在一般人及不同種的人表現上是有相當大的差異，而這些差異會造成個體對於藥物在體內的廓清，及如癌症等疾病的感受性不同。本文利用PCR-RFLP的方法分析CYP3A5基因多形性的變。結果顯示，在113例肝癌、70例子宮頸癌、92例乳癌、82例口腔癌、90例甲狀腺癌、133例肺癌及270位健康人中，其CYP3A5*1的發生率分別為25％、33％、31％、22％、23％、20％及27％。經過進一步分析後，發現只有肺癌組有統計上的意義（其P=0.028，OR=1.49，95%CI=1.04-2.13）。因此，我們認為CYP3A5*1在台灣人的肺癌形成扮演相尚重要的角色。

關鍵字

CYP3A5 ； 多形性變 ； 肺癌

並列摘要

The expression of the cytochrome P450 CYP3A5 enzymes shows a wide variation across the general population and ethnic groups. This wide disparity implies interracial differences in drug clearance and susceptibility to diseases such as cancer. CYP3A5 polymorphisms were rapidly determined using polymerase chain reaction-restriction fragment length polymorphism analysis in 113 Taiwanese patients with hepatoma, 70 with cervical cancer, 92 with breast cancer, 82 with oral cancer, 90 with thyroid cancer ,133 with lung cancer ,and 270 healthy controls. The allelic frequencies of CYP3A5*1 were 25%in hepatoma patients, 3%in cervical cancer patients, 31%in breast cancer patients,22% in oral cancer patients, and 27% in healthy subjects .Lung cancer patients had a significantly lower frequency (20%)of CYP3A5*1 expression than healthy controls(p=0.028,odds ratio=1.49, 95% confidence interval=1.04-2.13),but there was no statistically significant difference between healthy controls and other cancers. We suggest that CYP3A5*1 may play an important role in individual predisposition to lung cancer in Taiwan.

並列關鍵字

CYP3A5 ； polymorphism ； lung cancer